Would you consider adjuvant chemotherapy for a patient with HR+/HER2- breast cancer, luminal type A on Mammaprint, after knowing that the patient had a poor response to neoadjuvant endocrine therapy?  

Would you no longer trust the prognostic value of Mammaprint knowing the poor response to endocrine therapy?



Answer from: Medical Oncologist at Community Practice